Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 73

Results For "S-1"

771 News Found

Aster DM Heathcare plans India expansion
Healthcare | August 16, 2021

Aster DM Heathcare plans India expansion

Investment of Rs 235 crores to add 411 beds in the next 18 months


Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22
News | August 16, 2021

Orchid Pharma reports net loss of Rs 30.90 cr in Q1FY22

EPS for the period at Rs. (7.57)


Apollo Hospitals PAT at Rs 489.28 cr. in Q1FY22
Healthcare | August 16, 2021

Apollo Hospitals PAT at Rs 489.28 cr. in Q1FY22

The hospital chain aggressively embarks on digitisation and is e-health ready


Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores
News | August 13, 2021

Aurobindo Pharma buys Cronus Pharma Specialities for Rs 420 crores

The acquisition will provide it with a foothold in the US $ 48 billion global animal health market


USFDA grants distinct indication for Chronic Sleep Disorder
Drug Approval | August 13, 2021

USFDA grants distinct indication for Chronic Sleep Disorder

Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder


JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22
News | August 13, 2021

JB Chemicals & Pharmaceuticals PAT at Rs. 118.9 cr for Q1 FY22

Domestic formulations business records 39 % growth while the international business revenue was largely flat as compared to Q1 FY21


HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY
Healthcare | August 13, 2021

HCG Q1 revenue at Rs 326.58 cr. 67 per cent increase YoY

Substantial reduction in losses


Aster DM Healthcare PAT at Rs 44.47 crores for Q1FY22
News | August 12, 2021

Aster DM Healthcare PAT at Rs 44.47 crores for Q1FY22

Income declines marginally


Natco Pharma PAT at Rs 75 crore for Q1FY22
News | August 12, 2021

Natco Pharma PAT at Rs 75 crore for Q1FY22

The company has strong product launches both in India and overseas